Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MIRM NASDAQ:MLTX NASDAQ:PTGX NASDAQ:TRVI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMIRMMirum Pharmaceuticals$73.87-2.2%$57.15$36.86▼$75.74$3.79B0.94930,933 shs1.08 million shsMLTXMoonLake Immunotherapeutics$55.75+1.7%$51.68$31.42▼$58.26$3.52B1.27416,945 shs607,821 shsPTGXProtagonist Therapeutics$59.05+1.6%$54.58$33.31▼$61.89$3.62B2.33657,634 shs792,267 shsTRVITrevi Therapeutics$7.26+0.7%$6.92$2.36▼$8.78$878.01M0.581.90 million shs1.56 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMIRMMirum Pharmaceuticals-2.20%+3.29%+44.50%+66.60%+68.38%MLTXMoonLake Immunotherapeutics+1.73%-0.25%+10.48%+42.73%+19.10%PTGXProtagonist Therapeutics+1.57%+2.73%+8.11%+24.89%+38.13%TRVITrevi Therapeutics+0.69%-3.84%-2.16%+11.69%+146.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMIRMMirum Pharmaceuticals3.2601 of 5 stars2.60.00.04.23.51.70.6MLTXMoonLake Immunotherapeutics1.78 of 5 stars3.41.00.00.02.22.50.0PTGXProtagonist Therapeutics2.1814 of 5 stars2.53.00.00.02.92.50.6TRVITrevi Therapeutics2.8032 of 5 stars4.61.00.00.02.12.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMIRMMirum Pharmaceuticals 3.13Buy$74.130.35% UpsideMLTXMoonLake Immunotherapeutics 2.78Moderate Buy$74.4333.50% UpsidePTGXProtagonist Therapeutics 3.00Buy$67.2013.80% UpsideTRVITrevi Therapeutics 3.20Buy$20.11177.01% UpsideCurrent Analyst Ratings BreakdownLatest TRVI, MIRM, MLTX, and PTGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/21/2025TRVITrevi TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$18.008/11/2025MIRMMirum PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy$89.008/8/2025MIRMMirum PharmaceuticalsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$77.00 ➝ $89.008/8/2025TRVITrevi TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetStrong-Buy ➝ Strong-Buy$29.00 ➝ $27.008/8/2025TRVITrevi TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$24.00 ➝ $22.008/7/2025MIRMMirum PharmaceuticalsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingStrong-Buy ➝ Strong-Buy8/7/2025PTGXProtagonist TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform8/7/2025MIRMMirum PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetMarket Outperform ➝ Market Outperform$79.00 ➝ $81.008/7/2025MIRMMirum PharmaceuticalsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$77.00 ➝ $82.008/7/2025MIRMMirum PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$73.00 ➝ $80.008/7/2025PTGXProtagonist TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$67.00 ➝ $69.00(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMIRMMirum Pharmaceuticals$336.89M11.02N/AN/A$5.08 per share14.54MLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$5.57 per shareN/APTGXProtagonist Therapeutics$434.43M8.46$4.59 per share12.87$10.74 per share5.50TRVITrevi TherapeuticsN/AN/AN/AN/A$1.63 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMIRMMirum Pharmaceuticals-$87.94M-$1.21N/AN/AN/A-13.65%-24.76%-8.50%11/11/2025 (Estimated)MLTXMoonLake Immunotherapeutics-$118.94M-$2.78N/AN/AN/AN/A-40.98%-35.81%11/6/2025 (Estimated)PTGXProtagonist Therapeutics$275.19M$0.7084.36N/AN/A24.88%8.12%7.41%11/6/2025 (Estimated)TRVITrevi Therapeutics-$47.91M-$0.42N/AN/AN/AN/A-41.44%-38.21%11/5/2025 (Estimated)Latest TRVI, MIRM, MLTX, and PTGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025TRVITrevi Therapeutics-$0.10-$0.09+$0.01-$0.09N/AN/A8/6/2025Q2 2025MIRMMirum Pharmaceuticals-$0.31-$0.12+$0.19-$0.12$107.91 million$127.79 million8/6/2025Q2 2025PTGXProtagonist Therapeutics-$0.53-$0.55-$0.02-$0.55$8.32 million$5.55 million8/5/2025Q2 2025MLTXMoonLake Immunotherapeutics-$0.73-$0.87-$0.14-$0.87N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ATRVITrevi TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMIRMMirum Pharmaceuticals1.213.132.97MLTXMoonLake Immunotherapeutics0.2116.6516.65PTGXProtagonist TherapeuticsN/A16.9716.97TRVITrevi TherapeuticsN/A22.4222.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMIRMMirum PharmaceuticalsN/AMLTXMoonLake Immunotherapeutics93.85%PTGXProtagonist Therapeutics98.63%TRVITrevi Therapeutics95.76%Insider OwnershipCompanyInsider OwnershipMIRMMirum Pharmaceuticals14.36%MLTXMoonLake Immunotherapeutics12.02%PTGXProtagonist Therapeutics4.90%TRVITrevi Therapeutics18.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMIRMMirum Pharmaceuticals14050.24 million43.02 millionOptionableMLTXMoonLake Immunotherapeutics264.23 million56.51 millionOptionablePTGXProtagonist Therapeutics12062.21 million59.16 millionOptionableTRVITrevi Therapeutics20121.78 million99.49 millionOptionableTRVI, MIRM, MLTX, and PTGX HeadlinesRecent News About These CompaniesTrevi Therapeutics (NASDAQ:TRVI) Hits New 52-Week High - Time to Buy?August 30 at 6:25 AM | marketbeat.comInvesco Ltd. Acquires 829,364 Shares of Trevi Therapeutics, Inc. $TRVIAugust 30 at 3:30 AM | marketbeat.comTrevi spikes as B. Riley reportedly cites deal prospectsAugust 28 at 10:53 AM | msn.comAffinity Asset Advisors LLC Takes $7.86 Million Position in Trevi Therapeutics, Inc. $TRVIAugust 28 at 9:02 AM | marketbeat.comTrevi Therapeutics to Participate in Upcoming September ConferencesAugust 28 at 7:30 AM | prnewswire.comTrevi Therapeutics (NASDAQ:TRVI) Now Covered by Morgan StanleyAugust 24, 2025 | americanbankingnews.comTrevi Therapeutics (NASDAQ:TRVI) Coverage Initiated by Analysts at Morgan StanleyAugust 23, 2025 | marketbeat.comMorgan Stanley Initiates Coverage of Trevi Therapeutics (TRVI) with Overweight RecommendationAugust 22, 2025 | msn.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $20.38 Average Price Target from AnalystsAugust 20, 2025 | americanbankingnews.comB. Riley Boosts Earnings Estimates for Trevi TherapeuticsAugust 19, 2025 | marketbeat.comB. Riley Increases Earnings Estimates for Trevi TherapeuticsAugust 19, 2025 | americanbankingnews.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Sold by XTX Topco LtdAugust 17, 2025 | marketbeat.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Rating of "Buy" from AnalystsAugust 16, 2025 | marketbeat.comPersistent Asset Partners Ltd Makes New $260,000 Investment in Trevi Therapeutics, Inc. (NASDAQ:TRVI)August 13, 2025 | marketbeat.comInformed Momentum Co LLC Invests $3.47 Million in Trevi Therapeutics, Inc. (NASDAQ:TRVI)August 13, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), DENTSPLY SIRONA (XRAY) and Arrowhead Pharmaceuticals (ARWR)August 13, 2025 | theglobeandmail.comTrevi Therapeutics: Optimism Amid Earnings Call InsightsAugust 13, 2025 | msn.comHC Wainwright Analysts Increase Earnings Estimates for TRVIAugust 12, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPSAugust 11, 2025 | marketbeat.comRaymond James Financial Issues Pessimistic Forecast for Trevi Therapeutics (NASDAQ:TRVI) Stock PriceAugust 10, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth PlansAugust 10, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTRVI, MIRM, MLTX, and PTGX Company DescriptionsMirum Pharmaceuticals NASDAQ:MIRM$73.87 -1.66 (-2.20%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$72.93 -0.94 (-1.28%) As of 08/29/2025 04:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.MoonLake Immunotherapeutics NASDAQ:MLTX$55.75 +0.95 (+1.73%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$56.61 +0.86 (+1.55%) As of 08/29/2025 06:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.Protagonist Therapeutics NASDAQ:PTGX$59.05 +0.91 (+1.57%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$59.96 +0.91 (+1.53%) As of 08/29/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.Trevi Therapeutics NASDAQ:TRVI$7.26 +0.05 (+0.69%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$7.22 -0.04 (-0.55%) As of 08/29/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
